JAK3 kinase inhibitors (Cellzome/GSK)

N/A

Report date: 2025/03/20 16:12:36
NME

Base Information

Drug NameJAK3 kinase inhibitors (Cellzome/GSK)
Drug Alias NameJanus kinase 3 inhibitors (Cellzome/GSK)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase JAK3 inhibitors
TargetsTyrosine-protein kinase JAK3
Therapy Area/IndicationsInflammation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCellzome Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCellzome GmbhGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsInflammation

Other Information

ATC CodeN/A
Related LinksN/A